Efficacy and Safety of Cinacalcet in Ca, P and iPTH Levels in Patients With Mild, Moderate and Severe SHPT — ACTIVE  

Hyperparathyroidism; Secondary, Renal Clinical Trial

Official title: A Multi-center Study Evaluating Efficacy and Safety of Cinacalcet Hydrochloride(HCL) in Calcium, Phosphorus and Intact Parathyroid Hormone(iPTH) Serum Levels in Chinese Chronic Kidney Disease(CKD) Hemodialysis(HD) Patients With Mild, Moderate and Severe Secondary Hyperparathyroidism(SHPT)

Status Completed

Clinical Trial Summary

1. To evaluate achievement ratio of iPTH,Calcium and phosphorus after taking Cinacalcet HCL in hemodialysis subjects with mild, moderate and severe SHPT; 2. To explore the impact of Cinacalcet HCL using on the combined use of drugs; 3. To explore the difference of patients who continued or discontinued Cinacalcet HCL in real-world period from 33rd to 52nd week.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Hyperparathyroidism
• Hyperparathyroidism, Secondary
• Hyperparathyroidism; Secondary, Renal
• Neoplasm Metastasis

• NCT number: NCT03123406
• Study type: Interventional
• Source: Kyowa Kirin Co., Ltd.
• Status: Completed
• Phase: Phase 4
• Start date: April 19, 2017
• Completion date: September 6, 2019